Page last updated: 2024-11-05

acridine half-mustard

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

acridine half-mustard: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

acridine half-mustard : A member of the class of aminoacridines that is acridine which is substituted by a methoxy group at position 2, chlorine at position 6, and a {3-[(2-chloroethyl)amino]propyl}amino group at position 9. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID28241
CHEMBL ID1088472
CHEBI ID132980
SCHEMBL ID6403098
MeSH IDM0045304

Synonyms (22)

Synonym
icr-191
brn 0444928
acridine half-mustard
acridine, 6-chloro-9-((3-((2-chloroethyl)amino)propyl)amino)-2-methoxy-
n-(2-chloroethyl)-n'-(6-chloro-2-methoxy-9-acridinyl)-1,3-propanediamine
1,3-propanediamine, n-(2-chloroethyl)-n'-(6-chloro-2-methoxy-9-acridinyl)-
CHEBI:132980
n-(2-chloroethyl)-n'-(6-chloro-2-methoxyacridin-9-yl)propane-1,3-diamine
17070-44-9
6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine
CHEMBL1088472
unii-96o8d10rm2
96o8d10rm2 ,
icr-191 free base
acridine, 6-chloro-9-((3-((2-chloroethyl)amino)propyl)amino)-2- methoxy-
1,3-propanediamine, n-(2-chloroethyl)-n'-(6-chloro-2-methoxy-9- acridinyl)-
SCHEMBL6403098
2-methoxy-6-chloro-9-(3-(2-chloroethyl)aminopropylamino)acridine
3-(2-chloroethylazaniumyl)propyl-(6-chloro-2-methoxyacridin-9-yl)azaniumdichloride
Q27271916
n~1~-(2-chloroethyl)-n~3~-(6-chloro-2-methoxyacridin-9-yl)propane-1,3-diamine
DTXSID10864731

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The toxic and mutagenic effects of the alkylating agents methylnitrosourea (MNU) and methylnitronitrosoguanidine (MNNG) and of the frameshift mutagen, ICR-191 were compared among 3 human diploid lymphoblast lines, MIT-2, WI-L2 and GM 130."( Comparison of toxicity and mutagenicity of methylnitrosourea, methylnitronitrosoguanidine and ICR-191 among human lymphoblast lines.
Andon, BM; Slapikoff, SA; Thilly, WG, 1980
)
0.26

Dosage Studied

ExcerptRelevanceReference
" Mutational dose-response studies with X-rays, ethyl methanesulfonate (EMS), and ICR-191 were conducted in 4 of these revertant cell lines."( Heritable alterations at the adenine phosphoribosyltransferase (APRT) locus in human lymphoblastoid cell lines.
Amundson, SA; Fortunato, JE; Liber, HL, 1992
)
0.28
" The UV dose-response curve of mus-26 showed a characteristic plateau in the range of 100-200 J/m2."( Epistasis, photoreactivation and mutagen sensitivity of DNA repair mutants upr-1 and mus-26 in Neurospora crassa.
Inoue, H; Ishii, C, 1989
)
0.28
" Luminescence of the A16 strain (luxE mutant) increased significantly after a few hours of such a treatment with various mutagenic agents, revealing a dose-response correlation."( A modified Vibrio harveyi mutagenicity assay based on bioluminescence induction.
Podgórska, B; Wegrzyn, G, 2006
)
0.33
" harveyi mutagenicity assay is rapid, sensitive and reveals a dose-response correlation for various mutagens."( A modified Vibrio harveyi mutagenicity assay based on bioluminescence induction.
Podgórska, B; Wegrzyn, G, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
aminoacridinesAcridines which are substituted in any position by one or more amino groups or substituted amino groups. Note that the term 'aminoacridine' is the International Prorietary Name (INN) for 9-aminoacridine.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID465476Mutagenic activity in Salmonella typhimurium TA97a assessed as increase in number of revertants at 0.002 ug/plate by Ames test absence of S9 fraction (Rvb=146+/- 8)2010Journal of natural products, Feb-26, Volume: 73, Issue:2
DNA-damaging, mutagenic, and clastogenic activities of gentiopicroside isolated from Cephalaria kotschyi roots.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (66)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (46.97)18.7374
1990's16 (24.24)18.2507
2000's14 (21.21)29.6817
2010's5 (7.58)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.95 (24.57)
Research Supply Index4.20 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (98.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]